Pacer Advisors’s CG Oncology CGON Stock Holding History

Pacer Advisors’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-290	Closed	-$9.15K	–	2588
2024 Q2	$9.15K	Buy	+290	New	+$10.1K	﹤0.01%	3563

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Pacer Advisors's CGON Position: Q3 2024 in Review

Pacer Advisors sold out of CG Oncology (CGON) in Q3 2024, closing a stake of 290 shares — an estimated $9.15K sold.

Pacer Advisors first reported a position in CGON in Q2 2024 and held it in 1 quarter. The position peaked at $9.15K in Q2 2024. 121 funds tracked by Wall St. Rank hold CGON as of Q3 2024.

Pacer Advisors reported no remaining CG Oncology position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 290 CG Oncology shares in Q3 2024, an estimated $9.15K.
Pacer Advisors first reported a position in CG Oncology in Q2 2024 and held it in 1 quarter.
Pacer Advisors's CG Oncology position peaked at $9.15K in Q2 2024.
121 funds tracked by Wall St. Rank held CG Oncology as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.